ArticleJournal for immunotherapy of cancer2026

PARP1-selective inhibitor DSB1559 demonstrates superior efficacy and antitumor immunity in triple-negative breast cancer.

Adam Nelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.